Dr. Jacobs grew up in Washington and Idaho watching his mother valiantly battle colorectal cancer for 24 years. She is his inspiration for becoming an oncologist. He graduated summa cum laude from Brigham Young University. He subsequently attended UT Southwestern Medical Center where he graduated top of his class and received his MD with Distinction in Research. Dr. Jacobs later completed specialty training in Radiation Oncology at Duke University. During his training he received prestigious national and international awards.
Dr. Jacobs has co-authored peer-reviewed manuscripts for a variety of cancer sites including prostate, breast, lung, gastrointestinal, genitourinary, gynecologic, brain, head and neck, and lymphoma. He is experienced in advanced radiation techniques including intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), stereotactic body radiation therapy (SBRT), stereotactic ablative radiotherapy (SABR), and stereotactic radiosurgery (SRS).
His hobbies include basketball, hiking, bowling, disc golf, and spending time with his wife, children, and dog.
Chief Radiation Oncology Resident, Duke University (2019-2020)
Presented more than 20 abstracts at national and international conferences, earning multiple awards including Best Abstract, Best Poster, Travel Grant and 9 Oral Presentations (2013-2019)
Graduated #1 of 242 medical students at University of Texas Southwestern (2015)
Physicians of Tomorrow Award, American Medical Association Foundation (2014)
Tylenol ‘Future Care’ Scholar - 1 of 10 chosen nationally (2012)
Graduate Scholar Award, Golden Key International Honor Society (2012)
Graduated Summa Cum Laude - top 1% of his class at Brigham Young University (2011)
Alpha Omega Alpha Honor Medical Society
American Board of Radiology (ABR)
American Society of Radiation Oncology (ASTRO)
Jacobs CD, Barak I, Jung SH, Rocke DJ, Kahmke RR, Suneja G, Mowery YM. Prediction model to estimate overall survival benefit of postoperative radiotherapy for resected major salivary gland cancers. Oral Oncology. 2022 Sept; 132:105955.